FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380987130> ?p ?o ?g. }

• W4380987130 endingPage "3218" @default.
• W4380987130 startingPage "3218" @default.
• W4380987130 abstract "The molecular events underlying the variable effectiveness of dopamine receptor type 2 (DRD2) agonists in pituitary neuroendocrine tumors (PitNETs) are not known. Besides the canonical pathway induced by DRD2 coupling with Gi proteins, the β-arrestin 2 pathway contributes to DRD2's antimitotic effects in PRL- and NF-PitNETs. A promising pharmacological strategy is the use of DRD2-biased agonists that selectively activate only one of these two pathways. The aim of the present study was to compare the effects of two biased DRD2 ligands, selectively activating the G protein (MLS1547) or β-arrestin 2 (UNC9994) pathway, with unbiased DRD2 agonist cabergoline in PRL- and NF-PitNET cells. In rat tumoral pituitary PRL-secreting MMQ cells, UNC9994 reduced cell proliferation with a greater efficacy compared to cabergoline (-40.2 ± 20.4% vs. -21 ± 10.9%, p < 0.05), whereas the G-protein-biased agonist induced only a slight reduction. β-arrestin 2 silencing, but not pertussis toxin treatment, reverted UNC9994 and cabergoline's antiproliferative effects. In a cabergoline-resistant PRL-PitNET primary culture, UNC9994 inhibited cell proliferation and PRL release. In contrast, in NF-PitNET primary cultures (n = 23), biased agonists did not show better antiproliferative effects than cabergoline. In conclusion, the preferential activation of the β-arrestin 2 pathway by UNC9994 improves DRD2-mediated antiproliferative effects in PRL-PitNETs, suggesting a new pharmacological approach for resistant or poorly responsive tumors." @default.
• W4380987130 created "2023-06-17" @default.
• W4380987130 creator A5007489715 @default.
• W4380987130 creator A5018415085 @default.
• W4380987130 creator A5027502310 @default.
• W4380987130 creator A5037434863 @default.
• W4380987130 creator A5044615622 @default.
• W4380987130 creator A5045625995 @default.
• W4380987130 creator A5056595248 @default.
• W4380987130 creator A5057116478 @default.
• W4380987130 creator A5063541023 @default.
• W4380987130 creator A5065428803 @default.
• W4380987130 creator A5073581097 @default.
• W4380987130 creator A5081784472 @default.
• W4380987130 creator A5084740005 @default.
• W4380987130 creator A5085671410 @default.
• W4380987130 date "2023-06-16" @default.
• W4380987130 modified "2023-09-29" @default.
• W4380987130 title "A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells" @default.
• W4380987130 cites W1966627438 @default.
• W4380987130 cites W1975211475 @default.
• W4380987130 cites W2002227637 @default.
• W4380987130 cites W2009892205 @default.
• W4380987130 cites W2019055295 @default.
• W4380987130 cites W2038660215 @default.
• W4380987130 cites W2042200793 @default.
• W4380987130 cites W2082956345 @default.
• W4380987130 cites W2087688448 @default.
• W4380987130 cites W2096024465 @default.
• W4380987130 cites W2112295694 @default.
• W4380987130 cites W2121473111 @default.
• W4380987130 cites W2126939509 @default.
• W4380987130 cites W2137235272 @default.
• W4380987130 cites W2140311750 @default.
• W4380987130 cites W2140864873 @default.
• W4380987130 cites W2145094745 @default.
• W4380987130 cites W2151647995 @default.
• W4380987130 cites W2166977877 @default.
• W4380987130 cites W2346011598 @default.
• W4380987130 cites W2397477281 @default.
• W4380987130 cites W2404937024 @default.
• W4380987130 cites W2559256288 @default.
• W4380987130 cites W2580439088 @default.
• W4380987130 cites W2746574162 @default.
• W4380987130 cites W2789770036 @default.
• W4380987130 cites W2794289519 @default.
• W4380987130 cites W2875327822 @default.
• W4380987130 cites W2888060905 @default.
• W4380987130 cites W3034028158 @default.
• W4380987130 cites W3131385477 @default.
• W4380987130 cites W3159359850 @default.
• W4380987130 cites W3174365678 @default.
• W4380987130 cites W4281644793 @default.
• W4380987130 doi "https://doi.org/10.3390/cancers15123218" @default.
• W4380987130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37370829" @default.
• W4380987130 hasPublicationYear "2023" @default.
• W4380987130 type Work @default.
• W4380987130 citedByCount "0" @default.
• W4380987130 crossrefType "journal-article" @default.
• W4380987130 hasAuthorship W4380987130A5007489715 @default.
• W4380987130 hasAuthorship W4380987130A5018415085 @default.
• W4380987130 hasAuthorship W4380987130A5027502310 @default.
• W4380987130 hasAuthorship W4380987130A5037434863 @default.
• W4380987130 hasAuthorship W4380987130A5044615622 @default.
• W4380987130 hasAuthorship W4380987130A5045625995 @default.
• W4380987130 hasAuthorship W4380987130A5056595248 @default.
• W4380987130 hasAuthorship W4380987130A5057116478 @default.
• W4380987130 hasAuthorship W4380987130A5063541023 @default.
• W4380987130 hasAuthorship W4380987130A5065428803 @default.
• W4380987130 hasAuthorship W4380987130A5073581097 @default.
• W4380987130 hasAuthorship W4380987130A5081784472 @default.
• W4380987130 hasAuthorship W4380987130A5084740005 @default.
• W4380987130 hasAuthorship W4380987130A5085671410 @default.
• W4380987130 hasBestOaLocation W43809871301 @default.
• W4380987130 hasConcept C126322002 @default.
• W4380987130 hasConcept C134018914 @default.
• W4380987130 hasConcept C170493617 @default.
• W4380987130 hasConcept C185592680 @default.
• W4380987130 hasConcept C2778258207 @default.
• W4380987130 hasConcept C2778938600 @default.
• W4380987130 hasConcept C2779064019 @default.
• W4380987130 hasConcept C2779832395 @default.
• W4380987130 hasConcept C44208683 @default.
• W4380987130 hasConcept C513476851 @default.
• W4380987130 hasConcept C71315377 @default.
• W4380987130 hasConcept C71924100 @default.
• W4380987130 hasConcept C86803240 @default.
• W4380987130 hasConcept C98274493 @default.
• W4380987130 hasConceptScore W4380987130C126322002 @default.
• W4380987130 hasConceptScore W4380987130C134018914 @default.
• W4380987130 hasConceptScore W4380987130C170493617 @default.
• W4380987130 hasConceptScore W4380987130C185592680 @default.
• W4380987130 hasConceptScore W4380987130C2778258207 @default.
• W4380987130 hasConceptScore W4380987130C2778938600 @default.
• W4380987130 hasConceptScore W4380987130C2779064019 @default.
• W4380987130 hasConceptScore W4380987130C2779832395 @default.
• W4380987130 hasConceptScore W4380987130C44208683 @default.
• W4380987130 hasConceptScore W4380987130C513476851 @default.

• next